Morgan Stanley
CRDL

Morgan Stanley’s Cardiol Therapeutics CRDL Stock Holding History

Morgan Stanley’s Portfolio CRDL Stock Details CRDL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$338K Sell
250,421
-94,042
-27% -$96.5K ﹤0.01% 5660
2025
Q4 		$329K Buy
344,463
+188,132
+120% +$197K ﹤0.01% 5719
2025
Q3 		$167K Buy
156,331
+56,450
+57% +$68.5K ﹤0.01% 5955
2025
Q2 		$136K Buy
99,881
+40,268
+68% +$46.9K ﹤0.01% 6014
2025
Q1 		$57.8K Sell
59,613
-144,930
-71% -$178K ﹤0.01% 6222
2024
Q4 		$262K Buy
204,543
+140,843
+221% +$237K ﹤0.01% 5684
2024
Q3 		$126K Buy
63,700
+36,400
+133% +$75.5K ﹤0.01% 5907
2024
Q2 		$55.1K Buy
+27,300
New +$57.9K ﹤0.01% 6138
2023
Q4 		– Sell
-100
Closed -$90 – 7842
2023
Q3 		$90 Buy
+100
New +$96 ﹤0.01% 7452
2023
Q1 		– Sell
-4,482
Closed -$2.29K – 7734
2022
Q4 		$2.29K Sell
4,482
-13,985
-76% -$8.53K ﹤0.01% 7336
2022
Q3 		$19K Buy
18,467
+12,664
+218% +$15.4K ﹤0.01% 6817
2022
Q2 		$7K Buy
5,803
+1,303
+29% +$1.85K ﹤0.01% 7310
2022
Q1 		$7K Sell
4,500
-4,551
-50% -$7.51K ﹤0.01% 7495
2021
Q4 		$17K Sell
9,051
-18,039
-67% -$49.8K ﹤0.01% 7272
2021
Q3 		$112K Buy
+27,090
New +$98.2K ﹤0.01% 6303

Other funds holding CRDL

MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
IA
Integrity Alliance Urbandale, Iowa $2.64B AUM 16.75% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Morgan Stanley's CRDL Position: Q1 2026 in Review

Morgan Stanley reduced its Cardiol Therapeutics (CRDL) stake by 27% in Q1 2026, selling an estimated $96.5K and leaving 250,421 shares worth $338K. The position accounts for ﹤0.01% of the portfolio, ranked #5660.

Morgan Stanley first reported a position in CRDL in Q3 2021 and has held it in 15 quarters since. 47 funds tracked by Wall St. Rank hold CRDL as of Q1 2026.

  • Morgan Stanley held 250,421 shares of Cardiol Therapeutics worth $338K as of Q1 2026.
  • Morgan Stanley sold 94,042 Cardiol Therapeutics shares in Q1 2026, an estimated $96.5K.
  • Cardiol Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5660 holding.
  • Morgan Stanley first reported a position in Cardiol Therapeutics in Q3 2021 and has held it in 15 quarters since.
  • 47 funds tracked by Wall St. Rank held Cardiol Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.